| Literature DB >> 35754690 |
Yan Li1, Changle Peng2, Meiwei Zhang2, Liangzhen Xie1, Jinjin Gao1, Yingji Wang3, Yuanhe Gao2, Lihui Hou1.
Abstract
Background: Exercise is one of the recommended interventions for polycystic ovary syndrome (PCOS), and current evidence has shown that Tai chi may have favorable effects. The objective of this randomized controlled pilot trial was to study the feasibility and potential effects of Tai chi for overweight/obese adolescents and young women with PCOS, so a future definitive randomized controlled trial (RCT) can be well designed and implemented. Materials andEntities:
Year: 2022 PMID: 35754690 PMCID: PMC9232331 DOI: 10.1155/2022/4291477
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Flow diagram of the participants through the study.
Characteristics of the study participants.
| Tai chi group ( | Self-monitored exercise group ( | |
|---|---|---|
| Age (years) | 23.2 ± 4.38 | 22.9 ± 4.64 |
| Weight (kg) | 74.99 ± 11.62 | 78.33 ± 13.45 |
| Height (m) | 1.62 ± 0.05 | 1.63 ± 0.05 |
| BMI (m/kg2) | 28.41 ± 4.03 | 29.57 ± 4.47 |
| Waist circumference (cm) | 97 ± 8.73 | 96.4 ± 13.67 |
| Hip circumference (cm) | 107.27 ± 7.9 | 106.95 ± 8.05 |
| Waist-to-hip ratio (cm/cm) | 0.9 ± 0.05 | 0.9 ± 0.08 |
Data are expressed as the mean ± standard deviation. BMI: body mass index; FG score: Ferriman–Gallwey score.
Primary outcome measure.
| Tai chi group ( |
| Self-monitored exercise group ( |
| Differences in changes between the groups at 3 months ( | |||
|---|---|---|---|---|---|---|---|
| Baseline | 3 months | Baseline | 3 months | ||||
| BMI (m/kg2) | 28.41 ± 4.03 | 27.39 ± 3.58 | 0.008Δ | 29.57 ± 4.47 | 29.62 ± 3.95 | 0.524 | 0.003 |
Data are expressed as the mean ± standard deviation. BMI: body mass index; indicates P < 0.05 vs. the self-monitored exercise group; Δ indicates P < 0.05 vs. baseline.
Characteristics of study participants.
| Tai chi group ( |
| Self-monitored exercise group ( |
| Differences between the groups at 3 months ( | |||
|---|---|---|---|---|---|---|---|
| Baseline | 3 months | Baseline | 3 months | ||||
| Weight (kg) | 74.99 ± 11.62 | 73.08 ± 11.55 | 0.009Δ | 78.33 ± 13.45 | 77.97 ± 12.1 | 0.547 | 0.203 |
| Waist-to-hip ratio (cm/cm) | 0.9 ± 0.05 | 0.9 ± 0.04 | 0.956 | 0.9 ± 0.08 | 0.91 ± 0.08 | 0.481 | 0.833 |
| FPG (mmol/L) | 4.89 ± 0.89 | 4.84 ± 0.54 | 0.542 | 4.79 ± 0.53 | 4.83 ± 0.38 | 0.997 | 0.964 |
| FINS ( | 20.08 ± 12.39 | 13.99 ± 8.2 | 0.035Δ | 19.35 ± 10.26 | 20.36 ± 14.1 | 0.275 | 0.073 |
| HOMA-IR | 4.51 ± 3.15 | 3.05 ± 1.82 | 0.042Δ | 4.07 ± 2.0 | 4.36 ± 3.12 | 0.396 | 0.094 |
| T (ng/dL) | 61.84 ± 20.96 | 49.89 ± 15.77 | 0.045Δ | 63.92 ± 26.49 | 66.59 ± 28.15 | 0.822 | 0.032 |
| AND (ng/mL) | 274.21 ± 146.29 | 312.71 ± 182.51 | 0.53 | 285.3 ± 146.62 | 296.83 ± 136.46 | 0.892 | 0.758 |
| SHBG (nmol/L) | 19.34 ± 10.78 | 22.74 ± 9.64 | 0.093 | 28.61 ± 37.42 | 23.24 ± 13.73 | 0.512 | 0.890 |
| DHEAS ( | 7.17 ± 5.26 | 5.16 ± 2.45 | 0.017Δ | 5.92 ± 2.66 | 4.98 ± 2.51 | 0.01Δ | 0.818 |
| LH (mIU/mL) | 9.25 ± 5.08 | 4.54 ± 1.45 | 0.09 | 11.11 ± 12.01 | 4.42 ± 1.1 | 0.253 | 0.779 |
| FSH (mIU/mL) | 4.54 ± 1.66 | 6.96 ± 3.6 | 0.748 | 4.45 ± 0.99 | 7.7 ± 5.01 | 0.882 | 0.581 |
| LH/FSH | 2.19 ± 1.09 | 1.58 ± 0.74 | 0.024Δ | 2.28 ± 1.65 | 1.74 ± 1.11 | 0.232 | 0.556 |
| E2 (pg/mL) | 58.81 ± 20.36 | 47.99 ± 18.42 | 0.052 | 62.2 ± 54.92 | 59.85 ± 19.16 | 0.68 | 0.049 |
| TG (mmol/L) | 1.79 ± 1.35 | 1.33 ± 0.61 | 0.308 | 2.29 ± 1.29 | 2.3 ± 1.25 | 0.475 | 0.006 |
| TC (mmol/L) | 4.13 ± 1.09 | 3.81 ± 0.66 | 0.431 | 4.78 ± 1.18 | 4.75 ± 1.32 | 0.585 | 0.11 |
| HDL-C (mmol/L) | 1.07 ± 0.28 | 1.07 ± 0.27 | 0.936 | 1.11 ± 0.21 | 1.12 ± 0.28 | 0.86 | 0.572 |
| LDL-C (mmol/L) | 2.63 ± 0.71 | 2.43 ± 0.65 | 0.368 | 3.01 ± 0.99 | 3.13 ± 0.99 | 0.893 | 0.009 |
| FG score (score) | 5.0 ± 2.52 | 4.71 ± 2.93 | 0.206 | 4.35 ± 2.58 | 5.0 ± 3.27 | 0.327 | 0.817 |
indicates P < 0.05 vs. the self-monitored exercise group; Δindicates P < 0.05 vs. baseline; data are expressed as the mean ± standard deviation. FPG: fasting plasma glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; T: testosterone; AND: androstadienone; SHBG: sex hormone-binding globulin; DHEAS: dehydroepiandrosterone sulfate; LH: luteinizing hormone; FSH: follicle-stimulating hormone; E2: oestradiol; TC: cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FG score: Ferriman–Gallwey score.